2nd Oct 2014 07:00
2 October 2014
Premaitha Health PLC
("the Company")
Grant of Options
Premaitha Health PLC, a molecular diagnostics company employing next generation DNA analysis technology to develop molecular diagnostic products, announces that, further to the disclosure made in the Company's admission document dated 13 June 2014, it has granted options to subscribe for ordinary shares of 10p each in the Company ("Ordinary Shares"), exercisable at a price of 10p per share, to the following directors of the Company:
Director No of options
Dr Stephen Little 10,555,984
Peter Collins 5,638,174
The options above are granted under the Company's unapproved option scheme and will only vest if there is a positive movement in earnings per share. The options become exercisable in respect of one third of the Ordinary Shares over which they are granted on the first, second and third anniversaries of the date of grant.
In addition, the Company has granted a further 11,769,638 options to staff and senior management to subscribe for Ordinary Shares under the Company's EMI scheme. The options are subject to the same vesting conditions as those of the directors above.
The total number of options granted is therefore 27,963,796, which represents 14.9 per cent. of the Company's existing ordinary share capital. This number is greater than the number of options as set out on page 132 of the admission document dated 13 June 2014 following a meeting of the remuneration committee.
-Ends-
For more information, please contact:
|
|
Premaitha Health plcDr Stephen Little, Chief Executive OfficerJoanne Cross, Marketing Communications | Tel: +44 (0) 7736 843052Email: [email protected] |
|
|
Cairn Financial Advisers LLP (NOMAD)Liam MurrayAvi Robinson | Tel: +44 (0) 20 7148 7900 |
|
|
Panmure Gordon (UK) Limited (Broker)Robert NaylorFreddy Crossley
| Tel: +44 (0) 20 7886 2500 |
Instinctif Partners (Media)Melanie Toyne Sewell / Jen Lewis
| Tel: +44 (0) 207 457 2020 |
Related Shares:
YGEN.L